Literature DB >> 8288906

Atopic dermatitis: recent trends in pathogenesis and therapy.

K D Cooper1.   

Abstract

Emerging concepts in the areas related to the pathogenesis and treatment of atopic dermatitis are reviewed. In particular, recent findings have revealed several key steps in the maintenance of a vicious circle of spongiotic dermatitis associated with elevated T-lymphocyte activation, hyperstimulatory Langerhans cells, defective cell-mediated immunity, and B-cell IgE overproduction. The discovery of specific IgE-binding structures on Langerhans cells provides a mechanism for Langerhans cells to capture and present IgE-targeted allergens to allergen-specific T cells. Furthermore, certain microbial allergens that tend to preferentially elicit IgE-type responses also elicit a T-cell response dominated by the IgE-inducing lymphokine interleukin 4. Repeated stimulation by activated Langerhans cells appears to induce just such a response. Abnormal biochemical responsiveness and mediator release by AD monocytes, mast cells, and eosinophils also participate in the sustainment or initiation of such a vicious circle, and contribute directly to the dermatitis as well. Developments in the areas of neuropeptides, genetics, microbial superantigens, and cytokine networks in the skin also appear to have promise in providing a rational link between immune defects and the inflammatory events in AD. Conventional therapy remains the mainstay of atopic dermatitis management; however, new therapies based upon the above concepts are being tested in clinical trials. Although the difficulty of objectively grading AD lesional activity and the high placebo response of AD patients hampers the interpretation of many reports, several types of approaches are coming into focus. The effectiveness of cyclosporin A, which targets T-cell activation and antigen presentation, indicates that additional agents with such activity should be effective, and verifies the criticality of these cells in AD pathogenesis. Therapy with biologic response modifiers, such as interferon gamma or thymopentin, is oriented toward normalization of imbalanced immune responsiveness, rather than direct suppression of the immune system. The mechanism of action of and toxicities of Chinese herbal mixtures require further investigation, but may reveal hitherto unconsidered avenues. Other recent therapeutic trials have focused on reduction of trigger factors, such as house dust mite exposure, foods, and the abnormal epidermal lipid barrier to irritation.

Entities:  

Mesh:

Year:  1994        PMID: 8288906     DOI: 10.1111/1523-1747.ep12371746

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  28 in total

1.  The high-affinity IgE receptor (FcepsilonRI) blocks apoptosis in normal human monocytes.

Authors:  N Katoh; S Kraft; J H Wessendorf; T Bieber
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26.

Authors:  N Katoh; S Hirano; M Suehiro; K Ikenaga; T Yamashita; N Sugawara; H Yasuno
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model.

Authors:  L Chen; O Martinez; L Overbergh; C Mathieu; B S Prabhakar; L S Chan
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

Review 4.  Atopic dermatitis and the nervous system.

Authors:  Laurent Misery
Journal:  Clin Rev Allergy Immunol       Date:  2011-12       Impact factor: 8.667

5.  Prevalence of producers of enterotoxins and toxic shock syndrome toxin-1 among Staphylococcus aureus strains isolated from atopic dermatitis lesions.

Authors:  H Akiyama; Y Toi; H Kanzaki; J Tada; J Arata
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

6.  Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis.

Authors:  Lin Chen; O Martinez; P Venkataramani; S-X Lin; B S Prabhakar; L S Chan
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

7.  Regulatory effects of cytokine production in atopic allergic reaction by gammi-danguieumja.

Authors:  Ho-Jeong Na; Hye-Young Shin; Na-Hyung Kim; Mi-Won Kwon; Eun-Jeong Park; Seung-Heon Hong; Nam-Il Kim; Hyung-Min Kim
Journal:  Inflammation       Date:  2004-10       Impact factor: 4.092

8.  'High dose' vs. 'medium dose' UVA1 phototherapy in italian patients with severe atopic dermatitis.

Authors:  A Pacifico; P Iacovelli; G Damiani; C Ferraro; S Cazzaniga; R R Z Conic; G Leone; A Morrone
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-12-28       Impact factor: 6.166

Review 9.  The genetics of atopic dermatitis.

Authors:  Yin-Hsiu Chien; Wuh-Liang Hwu; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2007-12       Impact factor: 8.667

10.  VCAM-1 blockade delays disease onset, reduces disease severity and inflammatory cells in an atopic dermatitis model.

Authors:  Lin Chen; Shao-xia Lin; Sanober Amin; Lut Overbergh; Giacomo Maggiolino; Lawrence S Chan
Journal:  Immunol Cell Biol       Date:  2010-01-12       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.